Perjeta (pertuzumab) is a prescription drug used in combination with Herceptin (trastuzumab) and docetaxel to treat HER2-positive, metastatic breast cancer which hasn’t been treated with either Herceptin or chemotherapy yet.
Manufacturer : Roche
Strengths available : 420mg
Storage : Store at temperature between 2°C to 8°C
Dosage : The initial dose of PERJETA is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes.
When administered with PERJETA, the recommended initial dose of trastuzumab is 8 mg/kg administered as a 90-minute intravenous infusion, followed every 3 weeks by a dose of 6 mg/kg administered as an intravenous infusion over 30 to 90 minutes.
PERJETA, trastuzumab, and docetaxel should be administered sequentially. PERJETA and trastuzumab can be given in any order. Docetaxel should be administered after PERJETA and trastuzumab. An observation period of 30 to 60 minutes is recommended after each PERJETA infusion and before commencement of any subsequent infusion of trastuzumab or docetaxel
Most common side effects are Hair loss, Low levels of white blood cells with or without fever, Diarrhea, Nausea